1
|
Ozturk T, Kucukhuseyin O, Eronat AP, Tuzuner MB, Daglar-Aday A, Saygili N, Kisakesen HI, Seyhan F, Velidedeoğlu M, Calay Z, Ilvan Ş, Yilmaz-Aydoğan H, Ozturk O, Isbir T. Preliminary Study: Prominent miRNAs of Breast Malignant Tissues Compared to Normal Tissues in Turkish Patients with Breast Cancer. Anticancer Res 2015; 35:5425-5432. [PMID: 26408705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
miRNA involvement has been observed in almost every type of cancer, including breast cancer. The etiology of abnormal expression of miRNAs in cancer is still not clearly understood. In order to obtain insight into miRNA de-regulation in breast cancer, we analyzed expression levels of five breast cancer-related miRNAs, miRNA21, miRNA155, miRNA19a, miRNA17-5p and let7a miRNA, in both malignant and neighboring non-tumoral paraffin-embedded tissues of 47 patients with invasive ductal breast cancer. The targeted miRNAs, and a reference snRNA, U6, were analyzed by real-time polymerase chain reaction. let7a Levels were significantly lower in patients with lymphatic invasion than in those without (p=0.047). miR21 was down-regulated in 93.3% of patients with necrosis [p=0.017 (Fisher's exact test (FE))], while at least one oncogenic miRNA was up-regulated in 87.3% of the patients with invasive ductal carcinoma [p=0.009 (FE)]. In addition, tumor-suppressor miRNA was down-regulated or unaltered in 65.8% of the patients with tumor grade 2 or 3 and in all with grade 1 [p=0.047 (FE)]. Based on this preliminary study, we suggest that these miRNAs, especially let7a and miRNA21, might be useful markers in follow-up of breast cancer and in prognosis.
Collapse
Affiliation(s)
- Tulin Ozturk
- Department of Pathology, Cerrahpasa Medical School, The Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Ozlem Kucukhuseyin
- Department of Molecular Medicine, The Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Allison Pinar Eronat
- Department of Molecular Medicine, The Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Mete Bora Tuzuner
- Department of Molecular Biology and Genetics, Istanbul Technical University, Istanbul, Turkey
| | - Aynur Daglar-Aday
- Department of Molecular Medicine, The Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Neslihan Saygili
- Department of Molecular Medicine, The Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Halil Ibrahim Kisakesen
- Department of Molecular Medicine, The Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey Department of Molecular Biology and Genetics, Istanbul Technical University, Istanbul, Turkey
| | - Fatih Seyhan
- Department of Molecular Medicine, The Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Mehmet Velidedeoğlu
- Department of General Surgery, Cerrahpasa Medical School, The Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Zerrin Calay
- Department of Pathology, Cerrahpasa Medical School, The Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Şennur Ilvan
- Department of Pathology, Cerrahpasa Medical School, The Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Hülya Yilmaz-Aydoğan
- Department of Molecular Medicine, The Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Oguz Ozturk
- Department of Molecular Medicine, The Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Turgar Isbir
- Department of Molecular Medicine, The Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
| |
Collapse
|